ZIVO Bioscience Q4 2022 Earnings Report

ZIVO Bioscience EPS Results

• Actual EPS: -$1.68
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

ZIVO Bioscience Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ZIVO Bioscience Announcement Details

• Quarter: Q4 2022
• Date: 3/14/2023
• Time: N/A

ZIVO Bioscience (NASDAQ:ZIVO), a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.